# Carlisle Companies Inc: Form 10-Q for the period ended Mar 31, 2020

- Company: [Carlisle Companies Inc](/companies/csl.md) (CIK 790051)
- Form: 10-Q
- Filed: 2020-04-23
- Accepted by EDGAR: Apr 23, 2020, 15:06 ET
- Period: 2020-03-31
- Accession: 0000790051-20-000084
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/790051/000079005120000084/csl-20200331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/790051/000079005120000084/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-01-01 to 2020-03-31 | $1.03bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-01-01 to 2020-03-31 | $751.8m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months, 2020-01-01 to 2020-03-31 | $14.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2020-01-01 to 2020-03-31 | $161.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-01-01 to 2020-03-31 | $102.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-01-01 to 2020-03-31 | $18.9m | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-01-01 to 2020-03-31 | $14.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-01-01 to 2020-03-31 | $61.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-01-01 to 2020-03-31 | $1.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-01-01 to 2020-03-31 | $1.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-01-01 to 2020-03-31 | 56,500,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2020-01-01 to 2020-03-31 | $53.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2020-01-01 to 2020-03-31 | $22.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2020-01-01 to 2020-03-31 | $28.3m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months, 2020-01-01 to 2020-03-31 | $120.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Current assets | at 2020-03-31 | $2.61bn | us-gaap:AssetsCurrent |
| Total assets | at 2020-03-31 | $6.30bn | us-gaap:Assets |
| Current liabilities | at 2020-03-31 | $602.7m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2020-03-31 | $2.58bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2020-03-31 | $900.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2020-03-31 | $2.52bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 45,327 characters.

Carlisle Companies Incorporated ("Carlisle", the "Company", "we", "us" or "our") is a diversified, global portfolio of niche brands and businesses that manufactures highly engineered products and solutions for its customers. Driven by our strategic plan, Vision 2025, Carlisle is committed to generating superior shareholder and stakeholder returns by combining an entrepreneurial management style under a center-led approach, and balanced capital deployment, all with a culture of responsible stewardship and continuous improvement as embodied in the Carlisle Operating System ("COS"). Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide a reader of our financial statements with a narrative from the perspective of Company management. All references to "Notes" refer to our Notes to Condensed Consolidated Financial Statements in Item 1 to this quarterly report on Form 10-Q.

### Executive Overview

Carlisle’s first-quarter sales and diluted earnings per share results were negatively affected by the coronavirus global pandemic ("COVID-19"). We are prudently adjusting our business operating norms in response to intensified and necessary health and safety guidelines, and a dramatic decline in demand. We intend to stay on a course of responsible business activity to maintain a stable foundation for the post-COVID-19 recovery.

Our top priority is the health and safety of our employees. We appointed a multi-disciplinary team to coordinate consistent monitoring and application throughout Carlisle of guidance from appropriate health authorities. We have implemented safety measures throughout, including social distancing, enhanced facility cleaning, travel restrictions, facility access restrictions and a telecommuting policy for eligible employees. The multi-disciplinary team shares and receives regular updates from divisional management and all employees receive regular updates from our Chief Executive Officer. All information regarding our health and safety measures and updates is posted on our website.

Due to our strong balance sheet, in the first quarter we were able to avoid layoffs and disruptions in our operations outside of health and safety or government mandated shutdowns, pay our dividend of $28.3 million, deploy $22.8 million into capital expenditures and invest $14.4 million into research and development. As of the end of the first quarter, we have a strong cash position of $1.2 billion with an additional $500.0 million undrawn on our revolving credit facility (the "Facility").

#### Summary of Financial Results

*(in millions, except per share amounts)*

|  | Three Months Ended March 31, 2020 | 2019 |
| --- | ---: | ---: |
| Revenues | $1,030.2 | $1,071.9 |
| Operating income | $102.7 | $114.7 |
| Operating margin percentage | 10.0% | 10.7% |
| Income from continuing operations | $61.8 | $77.4 |
| Income from discontinued operations | $— | $2.0 |
| Diluted earnings per share attributable to common shares: |  |  |
| Income from continuing operations | $1.09 | $1.33 |
| Income from discontinued operations | $— | $0.03 |
| Items affecting comparability:(1) |  |  |
| Impact to operating income | $10.2 | $7.2 |
| Impact to income from continuing operations | $11.4 | $4.8 |
| Impact on diluted EPS from continuing operations | $0.20 | $0.08 |

(1) Items affecting comparability primarily include acquisition related costs, exit and disposal costs, facility rationalization costs, litigation settlement costs, gains from divestitures, excess capacity and labor costs, net of subsidies, losses on debt extinguishment and discrete tax items. Tax effect is based on the rate of the jurisdiction where the expense is deductible. Refer to *Items Affecting Comparability* in this MD&A for further information.

Revenues decreased in the first quarter of 2020 primarily reflecting lower volumes in our CIT, Carlisle Brake & Friction ("CBF") and Carlisle Fluid Technologies ("CFT") segments, which were impacted by the global economic slowdown due to COVID-19. Contributions from acquisitions, primarily of Providien LLC ("Providien"), partially offset the decrease in volume.

The decrease in operating income in the first quarter of 2020 primarily reflected the above revenue performance, wage inflation and expensed costs normally capitalized to inventory as a result of lower production or facility closures related to COVID-19. The decrease in operating income was partially offset by raw material savings.

Diluted earnings per share from continuing operations decreased primarily from the above operating income performance ($0.16 per share in the first quarter of 2020). The decrease was partially offset by a lower effective tax rate ($0.06 per share in the first quarter of 2020) and reduced average shares outstanding ($0.03 per share in the first quarter of 2020) resulting from our share repurchase program.

We generated $53.2 million in operating cash flows in the first quarter of 2020, and utilized cash on hand and cash provided by operations to return capital to shareholders through dividends and share repurchases, and fund capital expenditures.

### Consolidated Results of Operations

### Revenues

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  | Acquisition Effect | Price / Volume Effect | Exchange Rate Effect |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $1,030.2 | $1,071.9 | $(41.7) | (3.9)% | 3.4% | (7.0)% | (0.3)% |

The decrease in revenues in the first quarter of 2020 primarily reflected lower sales volume in our CIT, CBF and CFT segments, which were impacted by the global economic slowdown due to COVID-19. CIT's volume decline was led by lower sales in the commercial aerospace market, CBF experienced sales volume declines primarily in its heavy equipment market, and CFT experienced a decline in sales volumes across all markets in which it operates. Partially offsetting the decrease was a contribution of $23.9 million of revenues from the acquisition of Providien in the CIT segment and increased sales volume at Carlisle Construction Materials ("CCM"), primarily from architectural metals.

### Gross Margin

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  |
| --- | ---: | ---: | ---: | ---: |
| Gross margin | $278.4 | $288.6 | $(10.2) | (3.5)% |
| Gross margin percentage | 27.0% | 26.9% |  |  |
| Depreciation and amortization | $31.5 | $22.6 |  |  |

Gross margin percentage (gross margin expressed as a percentage of revenues) in the first quarter of 2020 was flat, driven by lower sales volume in our CIT, CFT and CBF segments and wage inflation, offset by favorable raw material pricing and purchase savings from COS. Also included in cost of goods sold were exit and disposal costs totaling $3.0 million for the first quarter of 2020, primarily at CBF and CIT, attributable to our restructuring initiatives, compared with $3.6 million for the first quarter of 2019. Refer to Note 8 for further information on exit and disposal activities.

### Selling and Administrative Expenses

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  |
| --- | ---: | ---: | ---: | ---: |
| Selling and administrative expenses | $161.9 | $164.2 | $(2.3) | (1.4)% |
| As a percentage of revenues | 15.7% | 15.3% |  |  |
| Depreciation and amortization | $24.7 | $25.9 |  |  |

The decrease in selling and administrative expenses in the first quarter of 2020 primarily reflected lower facility rationalization and plant restructuring costs (refer to Note 8), lower incentive compensation costs, lower legal and other administrative costs related to acquisitions, and lower medical costs. The decreases were partially offset by wage inflation.

### Research and Development Expenses

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  |
| --- | ---: | ---: | ---: | ---: |
| Research and development expenses | $14.4 | $14.4 | $— | —% |
| As a percentage of revenues | 1.4% | 1.3% |  |  |
| Depreciation and amortization | $0.6 | $0.5 |  |  |

Research and development expenses were flat in the first quarter of 2020, compared with the first quarter of 2019, and primarily reflected new product development at our CIT and CCM segments.

### Other Operating Income, net

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  |
| --- | ---: | ---: | ---: | ---: |
| Other operating income, net | $(0.6) | $(4.7) | $4.1 | 87.2% |

Other operating income, net in the first quarter of 2020 primarily reflected $0.5 million of rebates and $0.3 million of royalty income, partially offset by $0.7 million of losses on sale of assets, primarily at CCM.

Other operating income, net in the first quarter of 2019 primarily reflected a $3.0 million gain on contingent consideration at CFT and $0.6 million of gains on sales of assets, primarily at CBF.

### Operating Income

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  |
| --- | ---: | ---: | ---: | ---: |
| Operating income | $102.7 | $114.7 | $(12.0) | (10.5)% |
| Operating margin percentage | 10.0% | 10.7% |  |  |

Refer to *Segment Results of Operations* within this MD&A for further information related to segment operating income results.

### Interest Expense, net

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  |
| --- | ---: | ---: | ---: | ---: |
| Interest expense, net | $18.9 | $16.3 | $2.6 | 16.0% |

Interest expense, net during the first quarter of 2020 primarily reflected higher long-term debt balances associated with our public offering of $750.0 million notes completed in February 2020, and draws on our revolving credit facility to increase cash on hand and enhance financial flexibility in light of uncertainty in global markets from COVID-19. Refer to Note 12 for further information on our long-term debt.

### Interest Income

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  |
| --- | ---: | ---: | ---: | ---: |
| Interest income | $(0.7) | $(2.6) | $1.9 | 73.1% |

Interest income decreased during the first quarter of 2020 primarily related to lower yields.

### Loss on Extinguishment of Debt

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  |
| --- | ---: | ---: | ---: | --- |
| Loss on extinguishment of debt | $8.8 | $— | $8.8 | NM |

Loss on extinguishment of debt in the first quarter of 2020 related to the early redemption in full of our $250.0 million aggregate principal amount of our outstanding 5.125% notes due December 15, 2020 (the “2020 Notes”). The 2020 Notes were redeemed on March 29, 2020 at the redemption price of $262.1 million. The redemption price included a premium of $8.4 million, along with $0.4 million of deferred issuance costs and resulted in a loss of $8.8 million.

### Other Non-operating Income, net

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  |
| --- | ---: | ---: | ---: | --- |
| Other non-operating income, net | $(0.5) | $(0.4) | $(0.1) | NM |

Other non-operating income, net, in the first quarter of 2020 primarily reflected foreign exchange gains from the strengthening of the U.S. Dollar, partially offset by release of a portion of the indemnification asset related to the Petersen acquisition resulting from escrow expirations.

Other-non operating income, net in the first quarter of 2019 primarily reflected the net impact of the resolution of certain tax uncertainties related to the Accella acquisition and release of the corresponding indemnification asset, and the weakening of the U.S. Dollar and related changes in foreign exchange losses.

### Income Taxes

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  |
| --- | ---: | ---: | ---: | ---: |
| Provision for income taxes | $14.4 | $24.0 | $(9.6) | (40.0)% |
| Effective tax rate | 18.9% | 23.6% |  |  |

The effective income tax rate on continuing operations for the first quarter of 2020 was 18.9%. The year-to-date provision for income taxes included taxes on earnings at an anticipated rate of 23.9% and a year-to-date net discrete tax benefit of $3.8 million. The year-to-date net discrete tax benefit relates primarily to a reduction of unrecognized income tax benefits of $2.8 million and excess tax benefits related to employee stock compensation of $1.0 million.

The effective income tax rate on continuing operations for the first quarter of 2019 was 23.6%, reflecting the anticipated full-year rate.

### Income from Discontinued Operations

Income from discontinued operations of $2.0 million for the first quarter of 2019 relates solely to the settlement of prior income tax positions.

### Segment Results of Operations

We continue to operate our facilities as essential businesses operations supporting essential businesses under state and local stay-at-home mandates, while adhering to all health and safety measures for onsite employees. We have taken several steps to address the overall effects of COVID-19 on Carlisle and continue to assess the risks and potential impacts on our businesses. We have developed plans and implemented actions to mitigate risks and enhance the performance of our businesses in an uncertain environment dependent largely on future developments, which are highly uncertain and cannot be predicted.

### Carlisle Construction Materials ("CCM")

CCM's manufacturing plants in the United Kingdom and the Netherlands that serve the European markets are the only CCM facilities that have undergone temporary suspensions of operations. However, CCM's business is positioned to perform well in a market downturn given the significant need for maintaining critical infrastructure, coupled with a strong and growing industry backlog and evidence that demand is merely delayed. Additionally, CCM is benefiting from lower input costs and a highly variable manufacturing cost structure. Most importantly, we are focused on maintaining the premium Carlisle Experience on which our customers have come to rely, and as we emerge from this crisis will become even more important.

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  | Acquisition Effect | Price / Volume Effect | Exchange Rate Effect |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $676.4 | $671.1 | $5.3 | 0.8% | 0.3% | 0.7% | (0.2)% |
| Operating income | $107.7 | $92.9 | $14.8 | 15.9% |  |  |  |
| Operating margin percentage | 15.9% | 13.8% |  |  |  |  |  |
| Depreciation and amortization | $24.8 | $22.6 |  |  |  |  |  |
| Items affecting comparability(1) | $0.6 | $1.6 |  |  |  |  |  |

(1) Items affecting comparability include excess capacity and labor costs, net of subsidies, of $1.1 million, acquisition related costs ($0.2 million in the first quarter of 2020 and $1.4 million in the first quarter of 2019), exit and disposal and facility rationalization costs ($0.1 million in the first quarter of 2020 and $0.2 million in the first quarter of 2019), and a gain of $(0.8) million from the sale of a business, refer to *Items Affecting Comparability.*

CCM’s revenue growth in the first quarter of 2020 primarily reflected higher sales volumes in architectural metals and European product lines, both driven by strong order intake. Delays in customer demand along with temporary restrictions on construction from government-imposed shutdowns from COVID-19 resulted in volume declines of nearly 10 percent in the last two weeks of the quarter, with Europe seeing declines double that. We anticipate second-quarter 2020 sales in North America will be impacted between 20 and 30 percent, compared with second-quarter 2019. Beyond that, we are unable to predict the extent and duration of impacts from COVID-19 at this time.

CCM’s operating margin percentage growth in the first quarter of 2020 primarily reflected raw material savings, particularly MDI, positive sales volume leverage and savings from COS, partially offset by wage inflation.

### Carlisle Interconnect Technologies ("CIT")

Operations at certain of CIT’s manufacturing facilities in the U.S. and China were temporarily suspended during the first quarter, and its operations in Nogales, Mexico, serving its commercial aerospace customers, which was closed by government mandate that impacted all manufacturing plants in that region beginning April 1, 2020, is slowly beginning to resume limited operations. The unprecedented downturn in the commercial aerospace industry negatively impacts CIT's business, but also provides an opportunity to accelerate and complete restructuring actions, many of which were contemplated in Vision 2025. We intend to continue building our medical technologies platform. CIT supplies components to customers making critical medical equipment to combat COVID-19. We believe CIT’s end market mix will shift as a result.

In January 2019, we announced we would relocate our aerospace connectors manufacturing operations in El Segundo, California, and Riverside, California, to our existing lower cost facilities in North America. This project is expected to take 12 to 18 months to complete. Total project costs are expected to be approximately $20.3 million, with approximately $0.4 million remaining to be incurred. As a result of these efforts, focused on improving operational efficiencies throughout the business, we anticipate costs related to plant restructuring and facility rationalization to be completed in the first half of 2020. Refer to Note 8 for further information regarding exit and disposal activities.

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  | Acquisition Effect | Price / Volume Effect | Exchange Rate Effect |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $224.5 | $246.4 | $(21.9) | (8.9)% | 10.9% | (19.7)% | (0.1)% |
| Operating income | $16.4 | $30.6 | $(14.2) | (46.4)% |  |  |  |
| Operating margin percentage | 7.3% | 12.4% |  |  |  |  |  |
| Depreciation and amortization | $19.1 | $14.5 |  |  |  |  |  |
| Items affecting comparability(1) | $5.3 | $4.9 |  |  |  |  |  |

(1) Items affecting comparability include excess capacity and labor costs, net of subsidies, of $1.9 million, exit and disposal and facility rationalization costs ($3.4 million in the first quarter of 2020 and $4.7 million in the first quarter of 2019) and acquisition related costs of $0.2 million in the first quarter of 2019, refer to *Items Affecting Comparability.*

CIT's revenue decline in the first quarter of 2020 primarily reflected lower volumes, led by the commercial aerospace market as a result of continued delays in the 737 Max production and the steep decline in passenger airline travel caused by COVID-19, partially offset by acquired product lines from Providien and MicroConnex, that sell into the medical device end markets utilizing those brand names. Our commercial aerospace business declined approximately 20 percent in the first quarter of 2020, accelerating into March, which saw sales levels down roughly 35 percent. We are anticipating declines up to 50 percent in the second quarter of 2020, compared with the second quarter of 2019, and will be rightsizing our commercial aerospace business to meet the reality of what we believe will be a longer recovery by eliminating variable costs and optimizing our footprint. Beyond that, we are unable to predict the extent and duration of impacts from COVID-19 at this time. We are hopeful that passenger airline travel will return to normal levels by mid-2021 and that airlines will continue to defer and not cancel orders, allowing their multi-year backlogs to be realized.

CIT’s operating margin percentage decreased in the first quarter of 2020, driven by lower volumes and wage inflation, partially offset by savings from COS.

### Carlisle Fluid Technologies ("CFT")

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  | Acquisition Effect | Price / Volume Effect | Exchange Rate Effect |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $58.3 | $63.1 | $(4.8) | (7.6)% | 12.0% | (18.8)% | (0.8)% |
| Operating income | $2.8 | $6.4 | $(3.6) | (56.3)% |  |  |  |
| Operating margin percentage | 4.8% | 10.1% |  |  |  |  |  |
| Depreciation and amortization | $6.2 | $5.7 |  |  |  |  |  |
| Items affecting comparability(1) | $0.3 | $(0.9) |  |  |  |  |  |

(1) Items affecting comparability include excess capacity and labor costs, net of subsidies, of $0.1 million, acquisition related costs of $0.2 million in the first quarter of 2020. Items affecting comparability also include exit and disposal and facility rationalization costs of $2.0 million, acquisition related costs of $0.1 million and a gain on contingent consideration of $(3.0) million in the first quarter of 2019, refer to *Items Affecting Comparability.*

CFT's revenue decreased in the first quarter of 2020, reflecting volume declines, customer plant closures and project delays caused by COVID-19, particularly in the industrial and automotive end markets in all geographic regions, partially offset by contributions from acquisitions. The pressures of Brexit, unresolved U.S. and China trade negotiations and meaningful downturn in global automotive production were exacerbated by the COVID-19 pandemic spread and will likely result in a second-quarter 2020 revenue decline of over 20 percent, compared with second-quarter 2019. Beyond that, we are unable to predict the extent and duration of impacts from COVID-19 at this time.

CFT’s operating margin percentage performance for the first quarter of 2020 declined, reflecting lower volumes, and non-recurrence of a gain from contingent consideration, partially offset by savings from COS.

### Carlisle Brake & Friction ("CBF")

CBF's manufacturing plant in Orzinouvi, Italy, which was closed by government mandate on March 12, 2020, is slowly beginning to resume operations. CBF has also temporarily suspended operations at its manufacturing plant in the United Kingdom, in response to declining customer demand and to qualify for government subsidies to offset employment costs.

*(in millions)*

| 2020 | Three Months Ended March 31, 2019 |  | Change% |  | Acquisition Effect | Price / Volume Effect | Exchange Rate Effect |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $71.0 | $91.3 | $(20.3) | (22.2)% | —% | (20.8)% | (1.4)% |
| Operating (loss) income | $(3.8) | $6.5 | $(10.3) | (158.5)% |  |  |  |
| Operating margin percentage | (5.4)% | 7.1% |  |  |  |  |  |
| Depreciation and amortization | $5.9 | $5.4 |  |  |  |  |  |
| Items affecting comparability(1) | $3.7 | $1.3 |  |  |  |  |  |

(1) Items affecting comparability include excess capacity and labor costs, net of subsidies, of $0.9 million and include exit and disposal and facility rationalization costs ($2.8 million in the first quarter of 2020 and $1.3 million in the first quarter of 2019), refer to *Items Affecting Comparability.*

CBF revenue decreased in the first quarter of 2020, reflecting difficult year-over-year volume comparisons in the heavy equipment and transportation markets, declines in demand due to plant closures from COVID-19, and foreign currency headwinds. Long periods of plant idling had a negative effect on CBF's first-quarter 2020 results, and we expect similar declines in the second quarter of 2020, compared with second-quarter 2019. Beyond that, we are unable to predict the extent and duration of impacts from COVID-19 at this time.

CBF's operating margin percentage decrease in the first quarter of 2020 was driven by lower volumes and higher restructuring and facility rationalization costs, partially offset by savings from COS.

### Liquidity and Capital Resources

A summary of our cash and cash equivalents by region follows:

*(in millions)*

|  | March 31, 2020 | December 31, 2019 |
| --- | ---: | ---: |
| Europe | $120.3 | $62.2 |
| North America (excluding U.S.) | 38.3 | 43.4 |
| China | 42.7 | 17.9 |
| Asia Pacific (excluding China) | 58.7 | 69.1 |
| International cash and cash equivalents | 260.0 | 192.6 |
| U.S. cash and cash equivalents | 927.7 | 158.6 |
| Total cash and cash equivalents | $1,187.7 | $351.2 |

We maintain liquidity sources primarily consisting of cash and cash equivalents as well as availability under our Facility. In the near term, cash on hand is our primary source of liquidity. The increase in cash and cash equivalents compared to December 31, 2019, was primarily related to our bond offering of $750.0 million and $500.0 million of draws on our Facility in order to increase cash on hand and enhance our financial flexibility in light of current uncertainty in global markets resulting from COVID-19. Partially offsetting the increase in cash was the early redemption of our $250.0 million notes due in December 2020. Additionally, during the first three months of 2020, we utilized cash on hand to fund share repurchases, capital expenditures and pay dividends to shareholders.

Cash held in China is subject to local laws and regulations that require government approval for conversion of such cash to U.S. Dollars, as well as for transfer of such cash outside of China.

Despite the current uncertainty in global markets resulting from COVID-19, we believe we have sufficient cash on hand, availability under the Facility and operating cash flows to meet our business requirements for at least the next 12 months. At the discretion of management, the Company may use available cash on non-operating purchases including capital expenditures for worldwide manufacturing, dividends, common stock repurchases, acquisitions and strategic investments.

We also anticipate we will have sufficient cash on hand, as well as available liquidity under the Facility, to pay outstanding principal balances of our existing notes by the respective maturity dates. Another potential source of liquidity is access to public capital markets, subject to market conditions. We may access the capital markets to repay the outstanding balance, if our sources of liquidity have been used for other strategic purposes by the time of maturity. Refer to *Debt Instruments* below.

### Sources and Uses of Cash and Cash Equivalents

*(in millions)*

|  | Three Months Ended March 31, 2020 | 2019 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $53.2 | $109.8 |
| Net cash used in investing activities | (24.3) | (224.4) |
| Net cash provided by (used in) financing activities | 813.0 | (173.1) |
| Effect of foreign currency exchange rate changes on cash | (5.4) | 0.7 |
| Change in cash and cash equivalents | $836.5 | $(287.0) |

#### Operating Activities

We generated operating cash flows of $53.2 million for the first three months of 2020 (including working capital uses of $96.0 million), compared with $109.8 million for the first three months of 2019 (including working capital uses of $39.7 million). Lower operating cash flows in the first three months of 2020 primarily reflect lower cash earnings from decline in volumes and growth in working capital.

#### Investing Activities

Cash used in investing activities of $24.3 million for the first three months of 2020 primarily reflected capital expenditures of $22.8 million. Cash used in investing activities of $224.4 million for the first three months of 2019 primarily reflected the acquisition of Petersen, net of cash acquired, for $202.0 million and capital expenditures of $23.3 million.

#### Financing Activities

Cash provided by financing activities of $813.0 million in the first three months of 2020 primarily reflected net proceeds from our bond offering, draws on the revolver in order to increase cash on hand and enhance financial flexibility in light of uncertainty in global markets resulting from COVID-19, partially offset by the early redemption of our senior notes due December 15, 2020 and financing costs associated with our bond offering. Additionally we used cash of $120.6 million for share repurchases and $28.3 million for dividend payments, reflecting the increased dividend of $0.50 per share. Cash used in financing activities of $173.1 million during the first three months of 2019 primarily reflected $157.1 million of share repurchases and $23.3 million of dividend payments.

### Debt Instruments

#### Senior Notes

On February 28, 2020, the Company completed a public offering of $750.0 million of notes with a stated interest rate of 2.75% due March 1, 2030 (the “2030 Notes”). The 2030 Notes were issued at a discount of $9.3 million, resulting in proceeds to the Company of $740.7 million. The Company incurred costs to issue the 2030 Notes of approximately $6.5 million, inclusive of underwriters’, credit rating agencies’ and attorneys’ fees, loss on treasury locks contract and other costs. The discount, issuance costs and loss on treasury locks are amortized to interest expense over the life of the 2030 Notes. Interest is paid each March 1 and September 1, commencing on September 1, 2020.

On February 28, 2020, we issued a notice for the redemption in full of our $250.0 million aggregate principal amount of its outstanding 5.125% notes due December 15, 2020 (the “2020 Notes”). The 2020 Notes were redeemed on March 29, 2020 at the redemption price of $262.1 million. We recognized a loss on extinguishment of debt totaling $8.8 million in the first quarter of 2020.

We also have senior unsecured notes outstanding of $350.0 million due November 15, 2022 (at a stated interest rate of 3.75%), $400.0 million due December 1, 2024 (at a stated interest rate of 3.5%) and $600.0 million due December 1, 2027 (at a stated interest rate of 3.75%) that are rated BBB by Standard & Poor’s and Baa2 by Moody’s.

#### Revolving Credit Facility (the "Facility")

On February 5, 2020, the Company entered into the Company's Fourth Amended and Restated Credit Agreement (the “Amendment”) administered by JPMorgan Chase Bank, N.A. Among other things, the Amendment extended the maturity date of the Facility from February 21, 2022, to February 5, 2025.

During the three months ended March 31, 2020, borrowings under the Facility totaled $500.0 million with a weighted average interest rate 2.5%. As of March 31, 2020, the Facility had an outstanding balance of $500.0 million with an effective interest rate of 2.0% and $500.0 million of availability. During the year ended and as of December 31, 2019 there were no borrowings under the Facility.

#### Debt Covenants

We are required to meet various restrictive covenants and limitations under our senior notes and revolving credit facility including certain leverage ratios, interest coverage ratios and limits on outstanding debt balances held by certain subsidiaries. We were in compliance with all covenants and limitations as of March 31, 2020 and December 31, 2019.

Refer to Note 12 for further information on our debt instruments.

### New Accounting Pronouncements

Refer to Note 2 for more information regarding new accounting pronouncements.

### Critical Accounting Estimates

Our significant accounting policies are more fully described in Note 1 to our Annual Report on Form 10-K for the year ended December 31, 2019. In preparing the Consolidated Financial Statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”), the Company’s management must make informed decisions which impact the reported amounts and related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and assumptions on which to base estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to revenue recognition, extended product warranties, goodwill and indefinite-lived intangible assets, valuation of long-lived assets, and income taxes on an ongoing basis. The Company bases its estimates on historical experience, terms of existing contracts, our observation of trends in the industry, information provided by our customers and information available from other outside sources, that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

### Subsequent Measurement of Goodwill

Goodwill is not amortized but is tested annually, or more often if impairment indicators are present, for impairment at a reporting unit level, based on a comparison of the fair value of the reporting unit with its carrying amount. Goodwill is tested for impairment via a one-step process by comparing the fair value of goodwill with its carrying amount. We recognize an impairment for the amount by which the carrying amount exceeds the fair value. We generally use both an income approach utilizing the discounted cash flow method ("DCF") and a market approach utilizing the public company market multiple method, when testing for impairment. The key techniques and assumptions used include:

| Valuation Technique | Key Assumptions |
| --- | --- |
| Discounted future cash flows | •Estimated future revenues •Earnings before interest, taxes, depreciation and amortization ("EBITDA") margins •Discount rates |
| Market multiple method | •Peer public company group •Financial performance of reporting units relative to peer public company group |

In the first quarter of 2020, changes in facts and circumstances and general market declines from COVID-19 resulted in reduced expectations of future operating results. We considered these circumstances and the potential long-term impact on cash flows associated with our reporting units and determined that an indicator of possible impairment existed within our CFT and CBF reporting units. Accordingly, we tested our goodwill for impairment as of March 31, 2020. Those reporting units were tested for impairment using the quantitative approach described above, resulting in fair value that exceeded the carrying amount for each of the reporting units. The carrying amount of goodwill for the CFT and CBF reporting units was $185.6 million and $96.4 million, respectively.

We will continue to closely monitor actual results versus expectations as well as whether and to what extent any significant changes in current events or conditions, including changes to the impacts of COVID-19 on our business, result in corresponding changes to our expectations about future estimated cash flows, the weighted average cost of capital and market multiples. If our adjusted expectations of the operating results, both in size and timing, of CFT and CBF do not materialize, if the WACC increases (based on increases in interest rates, market rates of return, and market volatility) or if market multiples decline, we may be required to record goodwill impairment charges, which may be material.

While we believe our conclusions regarding the estimates of fair value of our reporting units are appropriate, these estimates are subject to uncertainty and by nature include judgments and estimates regarding various factors. These factors include the rate and extent of growth in the markets that our reporting units serve, the realization of future sales price and volume increases, fluctuations in exchange rates, fluctuations in price and availability of key raw materials, future operating efficiencies and, as it pertains to discount rates, the volatility in interest rates and costs of equity.

Refer to Note 11 for more information regarding goodwill.

### Subsequent Measurement of Indefinite-Lived Intangible Assets

As discussed above, indefinite-lived intangible assets are recognized and recorded at their acquisition-date fair value. Intangible assets with indefinite useful lives are not amortized but are tested annually at the appropriate unit of account, which generally equals the individual asset, or more often if impairment indicators are present. Indefinite-lived intangible assets are tested for impairment via a one-step process by comparing the fair value of the intangible asset with its carrying amount. We recognize an impairment charge for the amount by which the carrying amount exceeds the intangible asset's fair value. We generally estimate the fair value of our indefinite-lived intangible assets consistent with the techniques noted above using our expectations about future cash flows, discount rates and royalty rates for purposes of the annual test. We monitor for significant changes in those assumptions during interim reporting periods. We also periodically re-assess indefinite-lived intangible assets as to whether its useful lives can be determined, and if so, we would begin amortizing any applicable intangible asset.

In the first quarter of 2020, changes in facts and circumstances and general market declines from COVID-19 resulted in reduced revenue expectations. We considered these circumstances and the potential long-term impact on revenues associated with its indefinite-lived trade names and determined that an indicator of possible impairment existed. Accordingly, we performed a quantitative impairment analysis to determine the fair values of its CFT and CBF indefinite-lived trade names using the method described above.

Based on the output of the analysis, we determined that the fair values of both the CFT and CBF indefinite-lived trade names exceeded their carrying amounts. Accordingly, no impairment charges were required as of March 31, 2020. The carrying amount of indefinite-lived trade names for CFT and CBF were $129.1 million and $42.0 million, respectively.

We will continue to closely monitor actual results versus expectations as well as whether and to what extent any significant changes in current events or conditions, including changes to the impacts of COVID-19 on our business, result in corresponding changes to our expectations about future estimated revenues and the weighted average cost of capital. If our adjusted expectations of the revenues, both in size and timing, of CFT and CBF trade names do not materialize or if the WACC increases (based on increases in interest rates, market rates of return, and market volatility), we may be required to record trade name impairment charges, which may be material.

Refer to Note 11 for more information regarding intangible assets.

### Items Affecting Comparability

Items affecting comparability include costs, and losses or gains related to, among other things, growth and profitability improvement initiatives and other events outside of core business operations (such as asset impairments, exit and disposal and facility rationalization charges, costs of and related to acquisitions, litigation settlement costs, gains and losses from and costs related to divestitures, excess capacity and labor costs, net of subsidies, losses on debt extinguishment and discrete tax items). Because these items affect our, or any particular operating segment's, financial condition or results in a specific period in which they are recognized, we believe it is appropriate to present the total of these items to provide information regarding the comparability of results of operations period to period. The components of items affecting comparability follows:

*(in millions, except per share amounts)*

|  | Three Months Ended March 31, 2020 Impact to Operating Income | Impact to Income from Continuing Operations |  | Impact to Diluted EPS from Continuing Operations | Three Months Ended March 31, 2019 Impact to Operating Income | Impact to Income from Continuing Operations | Impact to Diluted EPS from Continuing Operations |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Exit and disposal costs | $4.8 | $3.6 |  | $0.06 | $6.8 | $5.1 | $0.09 |
| Other facility rationalization costs | 1.5 | 1.1 |  | 0.02 | 1.4 | 1.1 | 0.02 |
| Acquisition related costs: |  |  |  |  |  |  |  |
| Inventory step-up amortization | 0.2 | 0.2 |  | — | 0.5 | 0.4 | — |
| Other acquisition costs | 0.5 | 0.4 |  | 0.01 | 1.5 | 1.1 | 0.02 |
| Excess capacity and labor costs, net of subsidies | 4.0 | 3.0 |  | 0.05 | — | — | — |
| Gain from contingent consideration | — | — |  | — | (3.0) | (3.0) | (0.05) |
| Gains from divestitures | (0.8) | (0.6) |  | (0.01) | — | — | — |
| Loss on debt extinguishment | — | 6.6 |  | 0.12 | — | — | — |
| Indemnification losses | — | 1.1 |  | 0.02 | — | — | — |
| Discrete tax items(1) | — | (4.0) | (2) | (0.07) | — | 0.1 | — |
| Total items affecting comparability | $10.2 | $11.4 |  | $0.20 | $7.2 | $4.8 | $0.08 |

(1) In order to provide better information to the user, items affecting comparability include all discrete tax items in this period and all comparative periods.

(2) Excludes $0.1 million of discrete tax items related to indemnification asset write-offs which had zero impact to income from continuing operations and EPS from continuing operations.

The impact to income from continuing operations reflects the tax effect of items affecting comparability based on the statutory rate in the jurisdiction in which the expense or income is deductible or taxable. The per share impact of items affecting comparability to each period is based on diluted shares outstanding using the two-class method (refer to Note 5).

### Outlook

#### Revenues

In light of current economic uncertainty caused by COVID-19, we have decided to withdraw full-year 2020 revenue guidance until a clearer picture emerges for our businesses. We are hopeful that the major airlines and aircraft manufacturers will find improved financial stability soon in order to improve our ability to make accurate forecasts in the future.

#### Cash Flows

Despite the current uncertainty in global markets resulting from COVID-19, we believe we have sufficient cash on hand, availability under the Facility and operating cash flows to meet our business requirements for at least the next 12 months. At the discretion of management, the Company may use available cash on non-operating purchases including capital expenditures for worldwide manufacturing, dividends, common stock repurchases, acquisitions and strategic investments.

Capital expenditures in 2020 are expected to be between $100 million and $120 million, which primarily includes continued investments in CCM and CIT facilities. Planned capital expenditures for 2020 include business sustaining projects, cost reduction efforts and new product expansion. In response to declining demand attributable to COVID-19, we may make selected adjustments to its expected capital expenditures in line with our capital deployment strategy.

### Forward-Looking Statements

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential or expected impacts of the global COVID-19 pandemic. Forward-looking statements generally use words such as "expect," "foresee," "anticipate," "believe," "project," "should," "estimate," "will," "plans," "intends," "forecast," and similar expressions, and reflect our expectations concerning the future. Such statements are made based on known events and circumstances at the time of publication and, as such, are subject in the future to unforeseen risks and uncertainties. It is possible that our future performance may differ materially from current expectations expressed in these forward-looking statements, due to a variety of factors such as: risks from the global COVID-19 pandemic, including, for example, expectations regarding the impact of COVID-19 on our businesses, including on customer demand, supply chains and distribution systems, production, our ability to maintain appropriate labor levels, our ability to ship products to our customers, our ability to obtain financial and tax benefits from the recently-passed CARES Act, our future results, or our full-year financial outlook; increasing price and product/service competition by foreign and domestic competitors, including new entrants; technological developments and changes; the ability to continue to introduce competitive new products and services on a timely, cost-effective basis; our mix of products/services; increases in raw material costs which cannot be recovered in product pricing; domestic and foreign governmental and public policy changes including environmental and industry regulations; threats associated with and efforts to combat terrorism; protection and validity of patent and other intellectual property rights; the successful integration and identification of our strategic acquisitions; the cyclical nature of our businesses; and the outcome of pending and future litigation and governmental proceedings. In addition, such statements could be affected by general industry and market conditions and growth rates, the condition of the financial and credit markets and general domestic and international economic conditions including interest rate and currency exchange rate fluctuations. Further, any conflict in the international arena may adversely affect general market conditions and our future performance. We undertake no duty to update forward-looking statements.

## Market risk

As filed, 272 characters.

There have been no material changes in the Company’s market risk for the three months ended March 31, 2020. For additional information, refer to "PART II—Item 7A. Quantitative and Qualitative Disclosures About Market Risk" of the Company’s 2019 Annual Report on Form 10-K.

## Controls and procedures

As filed, 861 characters.

a. Evaluation of disclosure controls and procedures. Under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, the Company carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon that evaluation and as of March 31, 2020, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures are effective.

b. Changes in internal controls. During the first three months of 2020, there were no changes in the Company's internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

## Risk factors

As filed, 2,570 characters.

Except as noted below, there have been no material changes in the Company's risk factors disclosed in "PART I—Item 1A. Risk Factors" in our 2019 Annual Report on Form 10-K.

***The Company is subject to risks arising from global pandemics including the coronavirus ("COVID-19") pandemic.***

The Company’s businesses operate in market segments currently being impacted by the COVID-19 pandemic. Operating during a global pandemic exposes the Company to a number of risks, including diminished demand for our products and our customers’ products, suspensions in the operations of our manufacturing facilities, maintenance of appropriate labor levels and our ability to ship products to our customers, interruptions in our supply chains and distribution systems, increases in operating costs related to pay and benefits for our employees, collection of trade receivables in accordance with their terms, potential impairment of goodwill and long-lived assets; all of which, in the aggregate, could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.

We have experienced, and expect to continue to experience, diminished demand for our products as a result of COVID-19. The decline in domestic and international passenger airline travel caused by COVID-19 is negatively impacting demand for our products sold to customers operating in the commercial aerospace industry. COVID-19 related government restrictions on construction and construction repair and replacement starts and delays in building approvals in certain regions, along with construction labor quarantining, are negatively impacting demand for our products sold to customers operating in the nonresidential construction materials industry. Operations at certain of our facilities around the globe have been temporarily suspended because of COVID-19 either by government health decree or due to declining customer demand. While these COVID-19 related impacts have not to date, in the aggregate, had a material adverse impact on the Company, we are unable to predict the extent or duration of these impacts as they will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the duration of the coronavirus outbreak, the timing and extent of increased passenger airline travel and nonresidential construction and construction repair and replacement activity, and the continued ability of our businesses to continue to operate within all applicable COVID-19 related government rules and regulations.

Filed Apr 23, 2020.
Source: SEC EDGAR, the filing index for accession 0000790051-20-000084. Last ingested by Listed: Nov 10, 2026, 16:42 ET. No prices; not investment advice.
